{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:03:14Z","timestamp":1790125394079,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Science and Technology Department of Jiangxi Province, China","award":["20141BBG70023"],"award-info":[{"award-number":["20141BBG70023"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.clinre.2016.09.012","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T14:02:19Z","timestamp":1478700139000},"page":"210-216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Thalidomide is a therapeutic agent that is effective in inducing and maintaining endoscopic remission in adult CD patients"],"prefix":"10.1016","volume":"41","author":[{"given":"Zhenhua","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunhua","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonghua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangdi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2016.09.012_bib0135","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn's disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2016.09.012_bib0140","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2016.09.012_bib0145","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10620-012-2371-5","article-title":"Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population","volume":"58","author":"Kappelman","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinre.2016.09.012_bib0150","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.04.007","article-title":"Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study","volume":"145","author":"Ng","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2016.09.012_bib0155","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.3748\/wjg.v12.i30.4807","article-title":"Etiopathogenesis of inflammatory bowel diseases","volume":"12","author":"Danese","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinre.2016.09.012_bib0160","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00042737-199903000-00010","article-title":"Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease","volume":"11","author":"Woywodt","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2016.09.012_bib0165","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/gut.43.2.203","article-title":"Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease","volume":"43","author":"Noguchi","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.clinre.2016.09.012_bib0170","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2016.09.012_bib0175","series-title":"Inflammatory bowel disease: diagnosis and therapeutics","first-page":"93","article-title":"State-of-the-art medical therapy of the adult patient with IBD: the immunomodulators","author":"Moffatt","year":"2011"},{"key":"10.1016\/j.clinre.2016.09.012_bib0180","first-page":"1429","article-title":"Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy","volume":"27","author":"Ordi-Ros","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinre.2016.09.012_bib0185","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2133.1983.tb04600.x","article-title":"Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus","volume":"108","author":"Knop","year":"1983","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinre.2016.09.012_bib0190","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(04)15952-7","article-title":"Leprosy","volume":"363","author":"Britton","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2016.09.012_bib0195","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinre.2016.09.012_bib0200","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/rheumatology\/40.8.933","article-title":"Beh\u00e7et's disease in UK children: clinical features and treatment including thalidomide","volume":"40","author":"Kari","year":"2001","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl A","key":"10.1016\/j.clinre.2016.09.012_bib0205","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.clinre.2016.09.012_bib0210","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.2013.280777","article-title":"Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial","volume":"310","author":"Lazzerini","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.clinre.2016.09.012_bib0215","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0016-5085(99)70277-5","article-title":"An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease","volume":"117","author":"Vasiliauskas","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2016.09.012_bib0220","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0016-5085(99)70276-3","article-title":"Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial","volume":"117","author":"Ehrenpreis","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2016.09.012_bib0225","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2036.2006.03211.x","article-title":"Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results","volume":"25","author":"Lazzerini","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2016.09.012_bib0230","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.cgh.2015.10.034","article-title":"Long-term outcomes of thalidomide therapy for adults with refractory Crohn's disease","volume":"14","author":"Simon","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2016.09.012_bib0235","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/apt.13057","article-title":"Long-term outcomes of thalidomide in refractory Crohn's disease","volume":"41","author":"Gerich","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2016.09.012_bib0240","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3748\/wjg.v17.i10.1286","article-title":"Treatment of pediatric refractory Crohn's disease with thalidomide","volume":"17","author":"Zheng","year":"2011","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.clinre.2016.09.012_bib0245","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1440-1746.2002.02564.x","article-title":"Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease","volume":"17","author":"Bariol","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"issue":"July (6)","key":"10.1016\/j.clinre.2016.09.012_bib0250","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/MCG.0000000000000122","article-title":"Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant of anti-TNF-\u03b1 drugs: report of 3 cases and literature review","volume":"48","author":"Scribano","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.clinre.2016.09.012_bib0255","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/apt.13181","article-title":"Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease","volume":"41","author":"Yang","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2016.09.012_bib0260","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/1744666X.2015.1027687","article-title":"The clinical implications of thalidomide in inflammatory bowel diseases","volume":"11","author":"Diamanti","year":"2015","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740116301425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740116301425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:25:02Z","timestamp":1761895502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740116301425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S2210740116301425"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2016.09.012","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thalidomide is a therapeutic agent that is effective in inducing and maintaining endoscopic remission in adult CD patients","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2016.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}